DrugPatentWatch Database Preview
MOVIPREP Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Moviprep, and when can generic versions of Moviprep launch?
Moviprep is a drug marketed by Salix Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has forty-seven patent family members in nineteen countries.
The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.
Summary for MOVIPREP
| International Patents: | 47 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 28 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MOVIPREP |
| DailyMed Link: | MOVIPREP at DailyMed |
Generic Entry Opportunity Date for MOVIPREP
Generic Entry Date for MOVIPREP*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for MOVIPREP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | MOVIPREP | ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate | FOR SOLUTION;ORAL | 021881-001 | Aug 2, 2006 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Salix Pharms | MOVIPREP | ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate | FOR SOLUTION;ORAL | 021881-001 | Aug 2, 2006 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for MOVIPREP
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Oral Solution | 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch | ➤ Subscribe | ➤ Try a Free Trial |
see a sample report or, see our see our flat-rate plans
International Patents for MOVIPREP
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2011144613 | ➤ Try a Free Trial |
| Canada | 2672427 | ➤ Try a Free Trial |
| Hong Kong | 1077196 | ➤ Try a Free Trial |
| Japan | 2012025732 | ➤ Try a Free Trial |
| Russian Federation | 2005116023 | ➤ Try a Free Trial |
| Russian Federation | 2519562 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
